Phospho-Keratin 17 (Ser44) Antibody			TE	Il Signaling	
Sto				Orders:	877-616-CELL (2355) orders@cellsignal.com
6				Support:	877-678-TECH (8324)
#351				Web:	info@cellsignal.com cellsignal.com
For Research Use Only. Not for L	lse in Diagnostic Proc	edures	3 Trask I	ane Danvers Mas	ssachusetts 01923 USA
Applications: Reactiv WB, FC-FP H	-	MW (kDa): 49	Source: Rabbit	UniProt ID: #Q04695	Entrez-Gene Id: 3872
Product Usage Information	Application				Dilution
	Western Blotting Flow Cytometry (Fixed	/Permeabilized)			1:1000 1:50
Storage	Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.				
Specificity / Sensitivity	Phospho-Keratin 17 (Se on Ser44.	er44) Antibody dete	cts endogenous level	s of keratin 17 only v	when phosphorylated
Species predicted to react based on 100% sequence homology:	Monkey				
Source / Purification	Polyclonal antibodies and to amino acids surround affinity chromatography	ding Ser44 of huma			
Background	Keratins (cytokeratins) are intermediate filament proteins that are mainly expressed in epithelial cells. Keratin heterodimers composed of an acidic keratin (or type I keratin, keratins 9 to 23) and a basic keratin (or type II keratin, keratins 1 to 8) assemble to form filaments (1,2). Keratin isoforms demonstrate tissue- and differentiation-specific profiles that make them useful as research biomarkers (1). Research studies have shown that mutations in keratin genes are associated with skin disorders, liver and pancreatic diseases, and inflammatory intestinal diseases (3-6). Keratin 17 has been shown to be involved in wound healing, a process that requires rapid remodelling of the cytoskeleton (7). Another process that requires cytoskeletal remodelling is cell growth. It has been shown that in keratin 17 null keratinocytes that signaling through the Akt/mTOR pathway fails to produce an increase in translation, cell size or growth, and that this defect is associated with abnormal localization of 14-3-3σ. Since in normal cells, 14-3-3σ associates with keratin 17, a model has been proposed whereby signaling through Akt/mTOR produces a sequestration of 14-3-3σ in the cytosol via its interaction with keratin 17, and this sequestration by keratin 17 is required for translation and cell growth. Phosphorylation of keratin 17 on Ser 44 is thought to provide a docking site for 14-3-3σ binding (8).				
Background References	1. Moll, R. et al. (1982) 2. Chang, L. and Goldm 3. Ramaekers, F.C. and 4. Lane, E.B. and McLe 5. Zatloukal, K. et al. (20 6. Owens, D.W. and Lau 7. Paladini, R.D. et al. (20 8. Kim, S. et al. (2006)	nan, R.D. (2004) Na I Bosman, F.T. (200 an, W.H. (2004) J F 004) J Pathol 204, 3 ne, E.B. (2004) J Pa 1996) J Cell Biol 13	4) <i>J Pathol</i> 204, 351- Pathol 204, 355-66. 367-76. athol 204, 377-85.		
Species Reactivity	Species reactivity is dete	ermined by testing in	n at least one approv	ed application (e.g., v	vestern blot).
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key	WB: Western Blotting FC-FP: Flow Cytometry (Fixed/Permeabilized)				

1/1/24, 10:32 AM Cross-Reactivity Key	 Phospho-Keratin 17 (Ser44) Antibody (#3519) Datasheet Without Images Cell Signaling Technology H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected 		
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.		
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.		
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.		